Login
$EBS
$5.75 -$0.04 (0.78%) Live

$EBS 8-K/A SEC Filings

Filed On Filing
03 Aug 2022 8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure

GAITHERSBURG, Md., August 1, 2022—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.

09 Sep 2021 8-K/A: Financial Statements and Exhibits

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEMS OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30 1. REQUISITION NO. 0000HCGE-2017-05523 PAGE 1 OF 28 2. CONTRACT NO. 200-2017-92634 3. AWARD/EFFECTIVE DATE 12/08/2016 4. ORDER NO. 5. SOLICI...

01 May 2020 8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure

Executes multi-faceted response to COVID-19 drawing upon longstanding investments in capabilities to address public health threats, as well as expertise in vaccines, therapeutics, and contract development and manufacturing

12 Dec 2018 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma condensed combined financial statements of:

12 Dec 2018 8-K/A: Financial Statements and Exhibits

We have audited the accompanying consolidated financial statements of Adapt Pharma Limited and its subsidiaries, which comprise the consolidated statements of financial position as of 31 December 2017 and 31 December 2016, and the relate...

12 Dec 2013 8-K/A: Regulation FD Disclosure

December 11, 2013 Emergent BioSolutions Planned Acquisition ofCangene Corporation Provided December 11, 2013 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statemen...

13 Jan 2011 8-K/A: Completion of Acquisition or Disposition of Assets

Statements of Operations for the Three and Six Months Ended June 30, 2010 and 2009

16 Aug 2010 8-K/A: Other Events
23 Oct 2007 8-K/A: Results of Operations and Financial Condition

EMERGENT BIOSOLUTIONS COMPLETES FIRST DELIVERY OF BIOTHRAX(r) (ANTHRAX VACCINE ADSORBED) TO THE DEPARTMENT OF HEALTH AND HUMAN SERVICES UNDER NEW CONTRACT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support